Patents by Inventor Reinhard Sarges

Reinhard Sarges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminophenyltetralin compounds
    Patent number: 4045488
    Abstract: A series of novel 4-phenyl-1,2,3,4-tetrahydro-1-naphthylamines, including their pharmaceutically acceptable acid addition salts and their cis- and trans-isomers, have been prepared. The trans-isomers are useful in the field of mental health as antidepressant agents and/or as psychomotor stimulants. The trans-isomer of N-methyl-4-phenyl-1,2,3,4-tetrahydro-1-naphthylamine represents a preferred embodiment.
    Type: Grant
    Filed: May 27, 1976
    Date of Patent: August 30, 1977
    Assignee: Pfizer Inc.
    Inventor: Reinhard Sarges
  • Aminophenyltetralin compounds
    Patent number: 4029731
    Abstract: A series of novel 4-phenyl-1,2,3,4-tetrahydro-1-naphthylamines, including their pharmaceutically acceptable acid addition salts and their cis- and trans-isomers, have been prepared. The trans-isomers are useful in the field of mental health as antidepressant agents and/or as psychomotor stimulants. The trans-isomer of N-methyl-4-phenyl-1,2,3,4-tetrahydro-1-naphthylamine represents a preferred embodiment.
    Type: Grant
    Filed: June 4, 1976
    Date of Patent: June 14, 1977
    Assignee: Pfizer Inc.
    Inventor: Reinhard Sarges
  • Combination therapy for Parkinson's disease
    Patent number: 3991207
    Abstract: Substituted 1,2,3,4-tetrahydro-1-naphthylamines, or their acid addition salts, as potentiating agents in combination therapy with L-Dopa for control of the symptoms of Parkinson's disease. N,N-Dimethyl-5-methoxy-8-chloro-1,2,3,4-tetrahydro-1-naphthylamine is the preferred embodiment.
    Type: Grant
    Filed: March 18, 1971
    Date of Patent: November 9, 1976
    Assignee: Pfizer Inc.
    Inventors: Reinhard Sarges, Albert Weissman
  • Piperidinesulfonylurea derivatives
    Patent number: 3987172
    Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a nitrogen-containing monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxynicotinic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-{4-[2-(2-methoxynicotinamid o)ethyl]-1-piperidinesulfonyl}-urea is a most preferred embodiment.
    Type: Grant
    Filed: July 25, 1975
    Date of Patent: October 19, 1976
    Assignee: Pfizer Inc.
    Inventors: George R. Evanega, Donald E. Kuhla, Reinhard Sarges
  • Benzenesulfonylurea derivatives
    Patent number: 3961065
    Abstract: Certain novel benzenesulfonylurea compounds derived from a nitrogen-containing carboxylic acid have been prepared by reacting an appropriate sulfonamide with an organic isocyanate or a tri-substituted urea equivalent thereof. The sulfonylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxy-nicotinic acid, of which 1-cyclohexyl-3-{4-[2-(5-bromo-2-methoxynicotinamido)ethyl]benzenesulfonyl} urea is a most preferred embodiment.
    Type: Grant
    Filed: January 30, 1975
    Date of Patent: June 1, 1976
    Assignee: Pfizer Inc.
    Inventors: Donald E. Kuhla, Reinhard Sarges
  • Composition comprising a benzenesulfonylurea hypoglycemic agent and method of treatment
    Patent number: 3961067
    Abstract: Several benzenesulfonylurea compounds derived from 4-methyl-5-thiazolecarboxylic acid have been prepared by reacting 4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonamide with an appropriate organic isocyanate or a trisubstituted urea equivalent thereof. The sulfonylureas so obtained are useful in therapy as oral hypoglycemic agents. 1-Cyclohexyl-3-{4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonyl }urea represents a preferred embodiment.
    Type: Grant
    Filed: October 21, 1974
    Date of Patent: June 1, 1976
    Assignee: Pfizer Inc.
    Inventors: Donald E. Kuhla, Reinhard Sarges, Hans E. Wiedermann
  • 4-Substituted-1-piperidinesulfonamides
    Patent number: 3944524
    Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a nitrogen-containing monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxynicotinic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endomethyl)-3-{4-[2-(2-methoxynicotinamido )ethyl]-1-piperidinesulfonyl}urea is a most preferred embodiment.
    Type: Grant
    Filed: January 28, 1975
    Date of Patent: March 16, 1976
    Assignee: Pfizer Inc.
    Inventors: George R. Evanega, Donald E. Kuhla, Reinhard Sarges